Clicky

Valbiotis SAS(ALVAL)

Description: Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.


Keywords: Diabetes Nutrition Clinical Trial Hypertension Cardiovascular Disease Cholesterol Non Alcoholic Fatty Liver Disease Hypercholesterolemia Nestlé Neurosteroids Sterols

Home Page: www.valbiotis.com

rue Paul Vatine
Périgny, 17180
France
Phone: 33 5 46 28 62 58


Officers

Name Title
Mr. Sébastien Peltier HDR, Ph.D. Co-Founder, Chairman of the Management Board & CEO
Mr. Sebastien Bessy COO & Member of the Management Board
Mr. Pascal Sirvent Ph.D. CSO & Member of the Management Board
Ms. Murielle Cazaubiel CMO & Member of the Management Board
Mr. Fedrick Pelong CFO & Director
Dr. Josep Infesta Head of Global Bus. Devel.
Mr. Philippe Sibour Chief Exec. Officer of Alliance Consulting

Exchange: PA

Country: FR

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.3811
Price-to-Sales TTM: 54.0583
IPO Date:
Fiscal Year End: December
Full Time Employees: 5000
Back to stocks